STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics ...
MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...
Hosted on MSN
GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth
GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel ...
Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a companion diagnostic for multiple targeted medications across several cancers. The ...
Oct. 28, 2025 3:43 PM ETGeneDx Holdings Corp. (WGS) Stock, WGSWW StockAI-Generated Earnings Calls Insights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback